Background <p>Acquired resistance to KRAS G12C inhibitor sotorasib remains a critical challenge in non-small cell lung cancer treatment. A deeper, rational understanding of resistance mechanisms can enable the development of therapeutic strategies to overcome resistance.</p> Methods <p>We established a syngeneic resistant model after prolonged AMG-510 treatment in C57BL/6 mice. In addition, the in vitro co-culture model and multiple methods including…
Tumor immune microenvironment facilitates resistance to KRAS G12C inhibitor sotorasib by altered PD-L1 expression.
Journal for ImmunoTherapy of Cancer | | Liu, S., Jiang, Y., Fu, Y., Wang, S., Fu, R., Gao, M., Zhao, Y., Chen, S., Yang, Y., Yang, W., Jia, L., Qin, M., Zhang, X., Cui, W., Wang, L.
Topics: lung-cancer, blood-cancer, immunotherapy, research
Read the full article at Journal for ImmunoTherapy of Cancer